Cambridge Investment Research Advisors, Inc. Biogen Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 3,207 shares of BIIB stock, worth $557,344. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,207

Previous 3,379 5.09%

Holding current value

$557,344

Previous $783,000 20.56%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$189.07 - $236.8 $32,520 - $40,729	-172 Reduced 5.09%	3,207 $622,000
Q2 2024 Jul 26, 2024	SELL	$190.52 - $236.72 $74,302 - $92,320	-390 Reduced 10.35%	3,379 $783,000
Q1 2024 Apr 24, 2024	SELL	$212.02 - $267.71 $362,130 - $457,248	-1,708 Reduced 31.18%	3,769 $813,000
Q4 2023 Feb 09, 2024	SELL	$222.59 - $267.94 $62,770 - $75,559	-282 Reduced 4.9%	5,477 $1.42 Million
Q3 2023 Oct 24, 2023	SELL	$253.3 - $285.89 $2.39 Million - $2.69 Million	-9,417 Reduced 62.05%	5,759 $1.48 Million
Q2 2023 Jul 13, 2023	BUY	$275.25 - $318.06 $1.27 Million - $1.47 Million	4,612 Added 43.66%	15,176 $4.32 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $1.3 Million - $1.48 Million	5,078 Added 92.56%	10,564 $2.94 Million
Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $89,868 - $109,192	-356 Reduced 6.09%	5,486 $1.52 Million
Q3 2022 Oct 17, 2022	SELL	$194.69 - $268.46 $44,973 - $62,014	-231 Reduced 3.8%	5,842 $1.56 Million
Q2 2022 Jul 13, 2022	BUY	$187.54 - $223.02 $52,886 - $62,891	282 Added 4.87%	6,073 $1.24 Million
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $137,770 - $173,583	-711 Reduced 10.94%	5,791 $1.22 Million
Q4 2021 Feb 03, 2022	SELL	$223.92 - $287.77 $145,548 - $187,050	-650 Reduced 9.09%	6,502 $1.56 Million
Q3 2021 Nov 02, 2021	BUY	$282.99 - $369.05 $185,641 - $242,096	656 Added 10.1%	7,152 $2.02 Million
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $104,118 - $166,713	-402 Reduced 5.83%	6,496 $2.25 Million
Q1 2021 May 07, 2021	BUY	$242.95 - $284.63 $172,494 - $202,087	710 Added 11.47%	6,898 $1.93 Million
Q4 2020 Feb 04, 2021	SELL	$236.26 - $355.63 $256,342 - $385,858	-1,085 Reduced 14.92%	6,188 $1.52 Million
Q3 2020 Oct 29, 2020	SELL	$264.77 - $305.71 $272,713 - $314,881	-1,030 Reduced 12.41%	7,273 $2.06 Million
Q2 2020 Jul 27, 2020	BUY	$258.66 - $342.55 $421,357 - $558,013	1,629 Added 24.41%	8,303 $2.22 Million
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $81,192 - $102,994	302 Added 4.74%	6,674 $2.11 Million
Q4 2019 Feb 04, 2020	BUY	$220.06 - $304.07 $319,967 - $442,117	1,454 Added 29.56%	6,372 $1.89 Million
Q3 2019 Nov 06, 2019	SELL	$217.44 - $243.88 $163,949 - $183,885	-754 Reduced 13.29%	4,918 $1.15 Million
Q3 2019 Oct 28, 2019	SELL	$217.44 - $243.88 $2,391 - $2,682	-11 Reduced 0.19%	5,672 $1.32 Million
Q2 2019 Aug 15, 2019	SELL	$219.29 - $241.72 $98,680 - $108,774	-450 Reduced 7.34%	5,683 $0
Q1 2019 May 08, 2019	BUY	$216.71 - $338.96 $18,853 - $29,489	87 Added 1.44%	6,133 $0
Q4 2018 Feb 05, 2019	BUY	$278.5 - $352.75 $56,814 - $71,961	204 Added 3.49%	6,046 $1.82 Million
Q3 2018 Nov 02, 2018	BUY	$293.51 - $383.83 $149,690 - $195,753	510 Added 9.56%	5,842 $0
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $37,855 - $45,115	147 Added 2.84%	5,332 $0
Q1 2018 May 09, 2018	SELL	$260.13 - $367.91 $156,078 - $220,746	-600 Reduced 10.37%	5,185 $0
Q4 2017 Feb 22, 2018	SELL	$307.64 - $344.58 $50,145 - $56,166	-163 Reduced 2.74%	5,785 $0
Q3 2017 Nov 07, 2017	BUY	$281.15 - $329.69 $146,198 - $171,438	520 Added 9.58%	5,948 $1.86 Million
Q2 2017 Aug 08, 2017	BUY	N/A	5,428	5,428 $1.47 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Biogen Inc. Transaction History